Effectivity and Safety of PFO Closure vs Medicine in Alleviating Migraine

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

440

Participants

Timeline

Start Date

August 12, 2021

Primary Completion Date

September 6, 2025

Study Completion Date

September 6, 2025

Conditions
PFO - Patent Foramen OvaleMigraine
Interventions
DEVICE

PFO closure device

Device PFO closure.

DRUG

Aspirin and clopidogrel

Aspirin 100mg qd for 6 months and clopidogrel 75mg qd administered for 1month after device implanted.

DRUG

Triptans

If migraine recurred, Triptans would be administered during the acute phase.

Trial Locations (21)

130033

China-Japan Friendship Hospital of Jilin University, Changchun

210006

Nanjing First Hospital, Nanjing

300222

Tianjin Chest Hospital, Tianjin

361016

Xiamen Cardiovascular Hospital Xiamen University, Xiamen

410008

Xiangya Hospital Central South University, Changsha

430022

Wuhan Asia Heart Hospital, Wuhan

430071

Zhongnan hospital of wuhan university, Wuhan

445099

Enshi Huiyi Hospital of Rheumatic Diseases, Enshi

476100

Shangqiu First People's Hospital, Shangqiu

510080

Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou

510120

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

510510

Guangdong Sanjiu Brain Hospital, Guangzhou

510630

The Eighth Affiliated Hospital, Sun Yat-sen University, Guangzhou

516003

Huizhou First People's Hospital, Huizhou

518020

Shenzhen People's Hospital, Shenzhen

518033

The Eighth Affiliated Hospital, Sun Yat-sen University, Guangzhou

524001

Affiliated Hospital of Guangdong Medical University, Zhanjiang

529000

Jiangmen Central Hospital, Jiangmen

530022

The First People's Hospital of Nanning, Nanning

614099

The people's hospital of Leshan, Leshan

030024

Shanxi Cardiovascular Hospital, Taiyuan

All Listed Sponsors
lead

Guangdong Provincial People's Hospital

OTHER